Compare TSAT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | DNA |
|---|---|---|
| Founded | 1969 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 835.7M |
| IPO Year | 2021 | 2020 |
| Metric | TSAT | DNA |
|---|---|---|
| Price | $40.30 | $9.94 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 5 | 3 |
| Target Price | ★ $65.70 | $8.00 |
| AVG Volume (30 Days) | 98.6K | ★ 3.4M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.01 | $5.37 |
| 52 Week High | $61.54 | $18.22 |
| Indicator | TSAT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 48.17 |
| Support Level | $44.96 | $6.75 |
| Resistance Level | $46.56 | $10.45 |
| Average True Range (ATR) | 2.10 | 1.67 |
| MACD | -0.14 | -0.34 |
| Stochastic Oscillator | 47.98 | 5.79 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.